Lilly to Expand its Pain Pipeline with Acquisition of SiteOne Therapeutics
INDIANAPOLIS, May 27, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. (“SiteOne”), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor […]
Lilly to Expand its Pain Pipeline with Acquisition of SiteOne Therapeutics Read More »